drugset / Trial / NCT07816666
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Phase 3
Not yet recruiting
600 enrolled
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGOG Foundation · collabVentana Medical Systems, Inc · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)
Timeline
- Start
- 2026-09-29
- Primary completion
- 2028-09-26
- Completion
- 2031-10-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Torvutatug samrotecan | Other / unclassified | — | Intravenous |